title: Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al.
abstract: BACKGROUND
  Parenteral injections of d-lysergic acid diethylamide (LSD), a serotonin 5-HT(2A) receptor agonist, enhance eyeblink conditioning. Another hallucinogen, (±)-1(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), was shown to elicit a 5-HT(2A)-mediated behavior (head bobs) after injection into the hippocampus, a structure known to mediate trace eyeblink conditioning.
  
  
  OBJECTIVE
  This study aims to determine if parenteral injections of the hallucinogens LSD, d,l-2,5-dimethoxy-4-methylamphetamine, and 5-methoxy-dimethyltryptamine elicit the 5-HT(2A)-mediated behavior of head bobs and whether intrahippocampal injections of LSD would produce head bobs and enhance trace eyeblink conditioning.
  
  
  METHODS
  LSD was infused into the dorsal hippocampus just prior to each of eight conditioning sessions. One day after the last infusion of LSD, DOI was infused into the hippocampus to determine whether there had been a desensitization of the 5-HT(2A) receptor as measured by a decrease in DOI-elicited head bobs.
  
  
  RESULTS
  Acute parenteral or intrahippocampal LSD elicited a 5-HT(2A) but not a 5-HT(2C)-mediated behavior, and chronic administration enhanced conditioned responding relative to vehicle controls. Rabbits that had been chronically infused with 3 or 10 nmol per side of LSD during Pavlovian conditioning and then infused with DOI demonstrated a smaller increase in head bobs relative to controls.
  
  
  CONCLUSIONS
  LSD produced its enhancement of Pavlovian conditioning through an effect on 5-HT(2A) receptors located in the dorsal hippocampus. The slight, short-lived enhancement of learning produced by LSD appears to be due to the development of desensitization of the 5-HT(2A) receptor within the hippocampus as a result of repeated administration of its agonist (LSD).
authors.affiliation: Department of Pharmacology and Physiology, Drexel University College of Medicine, 245 N. 15th Street, 8th Floor, NCB, Mail stop # 488, Philadelphia, PA 19102, USA. anthony.romano@drexelmed.edu
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Romano
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Quinn
authors.forename: Luchuan
authors.initials: L
authors.lastname: Li
authors.forename: Kuldip D
authors.initials: KD
authors.lastname: Dave
authors.forename: Emmanuelle A
authors.initials: EA
authors.lastname: Schindler
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Aloyo
authors.forename: John A
authors.initials: JA
authors.lastname: Harvey
mesh_terms: D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001767:Blinking / Q000187:drug effects; D003214:Conditioning, Classical / Q000187:drug effects; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology; D019416:Head Movements / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007267:Injections; D007858:Learning / Q000187:drug effects; D008238:Lysergic Acid Diethylamide / Q000008:administration & dosage / Q000494:pharmacology*; D008732:Methoxydimethyltryptamines / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects* / Q000378:metabolism; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D006213:Hallucinogens; D008732:Methoxydimethyltryptamines; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D017366:Serotonin Receptor Agonists; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D008238:Lysergic Acid Diethylamide
references.citation: Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):735-40
references.pmid: 9435262
references.citation: Pharmacol Rev. 1972 Mar;24(1):31-66
references.pmid: 4626282
references.citation: J Pharmacol Exp Ther. 1982 May;221(2):289-94
references.pmid: 6122729
references.citation: Neurosci Lett. 1990 Jul 17;115(1):74-80
references.pmid: 2216059
references.citation: J Neurosci. 2002 Apr 1;22(7):2843-54
references.pmid: 11923449
references.citation: Behav Brain Res. 1996;73(1-2):47-50
references.pmid: 8788476
references.citation: Psychopharmacology (Berl). 2004 Apr;172(4):435-42
references.pmid: 14685644
references.citation: Psychopharmacology (Berl). 2004 Nov;176(3-4):287-95
references.pmid: 15107968
references.citation: Pharmacol Ther. 2004 Feb;101(2):131-81
references.pmid: 14761703
references.citation: Behav Neurosci. 1990 Apr;104(2):243-52
references.pmid: 2346619
references.citation: Behav Pharmacol. 1991 Jun;2(3):225-231
references.pmid: 11224066
references.citation: J Pharmacol Exp Ther. 1979 Feb;208(2):330-4
references.pmid: 762668
references.citation: Psychopharmacology (Berl). 1998 May;137(2):157-63
references.pmid: 9630002
references.citation: Science. 1998 Apr 3;280(5360):77-81
references.pmid: 9525860
references.citation: J Pharmacol Exp Ther. 1995 Apr;273(1):101-12
references.pmid: 7714755
references.citation: Behav Neurosci. 1986 Oct;100(5):729-44
references.pmid: 3778636
references.citation: J Pharm Sci. 1980 Feb;69(2):192-5
references.pmid: 6102141
references.citation: J Pharm Pharmacol. 1957 Sep;9(9):569-87
references.pmid: 13463749
references.citation: J Pharmacol Exp Ther. 2001 Dec;299(3):1066-72
references.pmid: 11714896
references.citation: Neurosci Biobehav Rev. 2002 May;26(3):309-19
references.pmid: 12034133
references.citation: Pharmacol Biochem Behav. 2004 Mar;77(3):623-9
references.pmid: 15006475
references.citation: J Physiol. 1991 Dec;444:459-80
references.pmid: 1822558
references.citation: J Pharmacol Exp Ther. 2007 Oct;323(1):327-35
references.pmid: 17640952
references.citation: Science. 1967 Nov 3;158(3801):669-70
references.pmid: 4860952
references.citation: Learn Mem. 2003 Sep-Oct;10(5):355-62
references.pmid: 14557608
references.citation: Pharmacol Biochem Behav. 1994 Feb;47(2):289-93
references.pmid: 7908446
references.citation: Eur J Pharmacol. 2000 Oct 13;406(2):163-9
references.pmid: 11020478
references.citation: Hippocampus. 1998;8(6):620-6
references.pmid: 9882019
references.citation: Pharmacol Ther. 2003 Apr;98(1):35-58
references.pmid: 12667887
references.citation: Pharmacol Biochem Behav. 2002 May;72(1-2):371-8
references.pmid: 11900808
references.citation: Pharmacol Ther. 2009 Feb;121(2):160-73
references.pmid: 19109993
references.citation: J Pharmacol Exp Ther. 2001 Oct;299(1):268-76
references.pmid: 11561089
references.citation: Psychopharmacology (Berl). 2006 Jan;184(2):173-81
references.pmid: 16369834